Noun
baricitinib (uncountable)
(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including rheumatoid arthritis and COVID-19.
Called baricitinib, and marketed under the brand name Olumiant, it is a relatively new drug for rheumatoid arthritis that has been available for only three years. Source: Internet
Indianapolis-based Lilly already sells baricitinib as Olumiant to treat rheumatoid arthritis, the less common form of arthritis that occurs when the immune system attacks joints, causing inflammation. Source: Internet
After 24 weeks of therapy, 67 percent of patients on a 4 mg dose of baricitinib showed a resolution of arthritis or rash, common symptoms of lupus, compared with 53 percent on a placebo. Source: Internet
Eli Lilly and Incyte will continue to work with the FDA on the drug application for baricitinib, he said. Source: Internet
WASHINGTON– Federal regulators have authorized emergency use of another COVID-19 treatment, the anti-inflammatory drug baricitinib, to be used in combination with a drug already used to treat severely ill, hospitalized patients. Source: Internet